Safety of virus plus antibiotics for cystic fibrosis lung infections
Part of Digestive system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This trial tests whether adding a special virus (bacteriophage) that kills antibiotic-resistant bacteria to standard IV antibiotics is safe for people with cystic fibrosis. It is for adults whose lung infections are hard to treat because the bacteria have stopped responding to usual antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of cystic fibrosis.
- Your most recent lung function test must be at least 40% of predicted, and if it's above 40%, you need to have had at least one serious lung infection per year or signs of severe lung damage.
- A sputum sample taken in the last 2 years must show one of the listed bacteria (like Pseudomonas or Staph) that is resistant to antibiotics.
- You must have been able to safely receive IV antibiotics at home within the past 5 years (or the study doctor may waive this).
- There must be a special virus (bacteriophage) available that can kill your specific lung bacteria.
- You cannot have untreated tuberculosis or certain other infections, a history of C. diff without a recent negative test, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
This trial tests a cocktail of viruses (bacteriophages) that target achromobacter bacteria in the lungs of adults with cystic fibrosis. It aims to see if the phages are safe and can reduce the infection.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests whether a cocktail of bacteriophages (viruses that kill bacteria) can treat ventilator-associated pneumonia caused by hard-to-treat bacteria like Klebsiella, Acinetobacter, or Pseudomonas. It may help patients who have not responded to standard antibiotics.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
Hear when a new Klebsiella Pneumoniae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.